查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1472342

全球腎上腺素市場：依產品類型、應用、通路：機會分析與產業預測（2023-2032）

Epinephrine Market By Product Type, By Application, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日期: | 出版商: Allied Market Research | 英文 266 Pages | 商品交期: 2-3個工作天內

價格

2022年全球腎上腺素市場規模為26億美元，預計2032年將達44億美元，2023年至2032年複合年成長率為5.6%。

腎上腺素，也稱為腎上腺素，是一種荷爾蒙和神經傳導物質，在身體對壓力和危險的反應中發揮重要作用。它是在位於腎臟頂部的腎上腺中產生的。腎上腺素會因各種刺激（包括恐懼、壓力和興奮）而釋放到血液中。一旦釋放，腎上腺素會引發一系列生理反應，旨在讓身體做好行動準備。這些反應包括增加心率、增加血壓、擴張肺部氣道以提高攝氧量以及將血流重新引導至肌肉。腎上腺素還可以提高警覺性和意識，幫助您對任務快速做出反應。

腎上腺素市場-IMG1

例如，它可用於治療過敏反應（嚴重過敏反應）、心臟麻痹、支氣管痙攣和其他心律不整。患者透過注射、吸入或鼻噴劑服用腎上腺素。因此，它可以透過空氣流入和能量可用性等機制來提高血液循環速度，為劇烈的體力消耗或感知到的威脅做好準備。

腎上腺素市場受到過敏反應、氣喘和食物過敏等過敏性疾病發生率增加的推動。這些可能會引起強烈且可能致命的反應，需要使用腎上腺素作為第一線治療。例如，根據美國過敏、氣喘和免疫學院 (ACAAI) 的數據，截至 2021 年，美國約有 2,000 萬人有食物過敏。過敏反應是一種嚴重的、有時致命的過敏反應，當患有災難性食物過敏的人意外接觸食物過敏原時，會導致呼吸困難、喉嚨腫脹和血壓突然下降。在這些情況下，及時服用腎上腺素對於解決危險症狀至關重要，這推動了對腎上腺素的需求。

此外，緊急醫療服務（EMS）的成長也有助於推動產業內的腎上腺素需求。處理各種危及生命的病例（例如心臟麻痹和過敏反應）的初期應變人員通常會服用這種藥物，因此成為其緊急醫療套件的一部分。緊急醫療服務的可用性和可近性的改善以及對緊急醫療護理的需求的增加極大地促進了腎上腺素需求的成長。

此外，人口老化也是腎上腺素市場成長的因素。隨著年齡的成長，我們更容易出現過敏反應和慢性呼吸道疾病，例如氣喘和慢性阻塞性肺病（COPD）。在這種情況下，腎上腺素有時被用作救命藥物，以控制嚴重症狀並預防併發症，從而支持市場成長。

然而，腎上腺素產品的監管挑戰和嚴格的核准流程可能會限制市場成長。為了確保腎上腺素製劑的安全性和有效性，監管機構經常對製造、標籤和分銷施加嚴格的標準，這可能會延遲產品上市，增加製造商的成本，並對市場成長產生負面影響。相較之下，藥物輸送系統的技術進步，例如開發更易於使用且更方便的腎上腺素自動注射器，提高了患者的依從性和市場滲透率。配方技術、包裝設計、設備易用性等方面的創新預計將為預測期內的市場成長創造利潤豐厚的機會。

腎上腺素市場按產品類型、應用、分銷管道和地區細分。依產品類型分類，市場分為自動注射器、預填充式注射器等。根據應用，市場分為過敏反應、心臟麻痹等。依銷售管道分為院內藥局、藥局/零售藥局、網路藥局。依地區分類，北美（美國、加拿大、墨西哥）、歐洲（德國、法國、英國、義大利、西班牙、其他歐洲國家）、亞太地區（日本、中國、澳洲、印度、韓國、其他亞太地區）、拉丁美洲（分析分為三個區域：巴西、哥倫比亞、阿根廷、其他拉丁美洲）、中東/非洲（海合會國家、南非、北非、其他中東/非洲）。

相關人員的主要利益

本報告定量分析了 2022 年至 2032 年腎上腺素市場分析的細分市場、當前趨勢、估計/趨勢和動態，以確定當前的腎上腺素市場機會。

我們提供市場研究以及與市場促進因素、市場限制和市場機會相關的資訊。

波特的五力分析強調買家和供應商幫助相關人員做出利潤驅動的商業決策並加強供應商-買家網路的潛力。

腎上腺素市場細分的詳細分析將有助於確定市場機會。

每個地區的主要國家都根據其對全球市場的收益貢獻繪製了地圖。

市場公司定位有助於基準化分析並提供對市場公司當前地位的清晰了解。

該報告包括對區域和全球腎上腺素市場趨勢、主要企業、細分市場、應用領域和市場成長策略的分析。

可以使用此報告進行報告客製化（請聯絡銷售人員以了解額外費用和時間表）

  • 監管指引
  • 根據客戶興趣加入公司簡介
  • 按國家或地區進行的附加分析：市場規模和預測
  • 公司簡介的擴充列表
  • 歷史市場資料
  • 主要企業詳細資料（Excel 格式，包括位置、聯絡資訊、供應商/供應商網路等）

目錄

第1章簡介

第 2 章執行摘要

第3章市場概況

  • 市場定義和範圍
  • 主要發現
    • 影響因素
    • 主要投資機會
  • 波特五力分析
  • 市場動態
    • 促進因素
    • 抑制因素
    • 機會

第4章腎上腺素市場：依產品類型

  • 概述
  • 自動注射器
  • 預填充式注射器
  • 其他

第5章腎上腺素市場：依應用分類

  • 概述
  • 過敏反應
  • 心臟麻痹
  • 其他

第6章 腎上腺素市場：依通路

  • 概述
  • 院內藥房
  • 藥局/零售藥房
  • 線上提供者

第7章 腎上腺素市場：依地區

  • 概述
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 其他
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 其他
  • 拉丁美洲
    • 巴西
    • 哥倫比亞
    • 阿根廷
    • 其他
  • 中東/非洲
    • 海灣合作理事會國家
    • 南非
    • 北非
    • 其他

第8章 競爭格局

  • 介紹
  • 關鍵成功策略
  • 10家主要企業產品圖譜
  • 競爭對手儀表板
  • 競爭熱圖
  • 主要企業定位（2022年）

第9章 公司簡介

  • Adamis Pharmaceuticals Corporation
  • AdvaCare Pharma
  • ALK
  • Amneal Pharmaceuticals LLC.
  • Amphastar Pharmaceuticals, Inc.
  • Grand Pharma（China）Co., Ltd.
  • kaleo, Inc.
  • Pfizer
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: A65539

The epinephrine market was valued at $2.6 billion in 2022 and is projected to reach $4.4 billion by 2032, registering a CAGR of 5.6% from 2023 to 2032. Epinephrine, also known as adrenaline, is a hormone and neurotransmitter that plays a vital role in the body's response to stress or danger. It is produced by the adrenal glands, located on top of the kidneys. Epinephrine is released into the bloodstream in response to various stimuli, such as fear, stress, or excitement. Once released, epinephrine triggers a series of physiological responses aimed at preparing the body for action. These responses include increased heart rate, elevated blood pressure, dilation of the airways in the lungs to improve oxygen intake, and redirection of blood flow to the muscles. Epinephrine also enhances alertness and awareness, helping individuals react quickly to challenging situations.

Epinephrine Market - IMG1

It can be used medicinally, for instance, during ana-phylaxis (severe allergic reactions), cardiac arrest, bronchospasm, or other arrhythmias. Patients take epinephrine by injection inhalers or even nasal sprays; thus, the result helps them get ready for intense physical exertions and/or perceived threats by increase in circulation rates of blood through such mechanisms as air entry and energy availability, among others.

The epinephrine market is driven by the increase in incidence of allergic conditions such as anaphylaxis, asthma, and food allergies. These in turn can provoke strong and potentially lethal reactions that can require epinephrine use as a first line treatment. For instance, according to the American College of Allergy, Asthma, and Immunology (ACAAI), as of 2021, about 20 million people had food allergies in the U.S. Anaphylaxis is a severe and sometimes fatal allergic response that causes breathing problems, throat swelling or a sudden fall in blood pressure if people with devastating food allergies are accidentally exposed to them. In these cases, quick administration of epinephrine is essential to counteract dangerous symptoms, which drives the demand for epinephrine.

In addition, the growth of emergency medical services (EMS) has also been instrumental in propelling the demand for epinephrine within the industry. Paramedics and first responders who attend various life-threatening cases such as cardiac arrest and anaphylaxis among others, are usually given this medicine and thus, it forms a part of their emergency medical kits. The increased availability and accessibility of emergency medical services coupled with rise in demand for emergency care have been key contributors to growth in demand for epinephrine.

Furthermore, the aging population is another factor contributing to the growth of the epinephrine market. As people age, they become more susceptible to allergic reactions and chronic respiratory conditions, such as asthma and chronic obstructive pulmonary disease (COPD). In these cases, epinephrine may be prescribed as a life-saving medication to manage severe symptoms and prevent complications, which supports the market growth.

However, the regulatory challenges and stringent approval processes for epinephrine products can limit market growth. Regulatory agencies often impose rigorous standards for the manufacturing, labeling, and distribution of epinephrine medications to ensure their safety and efficacy lead to delays in product launches and increased costs for manufacturers, which negatively impacted the market growth. In contrast, technological advancements in drug delivery systems, such as the development of more user-friendly and convenient epinephrine auto-injectors, enhance patient compliance and market penetration. Such innovations in formulation techniques, packaging designs, and device usability are expected to create lucrative opportunities for market growth during the forecast period.

The epinephrine market is segmented on the basis of product type, application, distribution channel, and region. By product type, the market is classified into auto-injector, prefilled syringe, and others. By application, the market is divided into anaphylaxis, cardiac arrest, and others. By distribution channel, it is segregated into hospital pharmacy, drug stores and retail pharmacy, and online pharmacy. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), LA (Brazil, Colombia, Argentina, and rest of LA), and MEA (GCC, South Africa, North Africa, and rest of MEA).

Major key players that operate in the epinephrine market are Adamis Pharmaceuticals Corporation, AdvaCare Pharma, ALK-Abello A/S, Amneal Pharmaceuticals LLC., Amphastar Pharmaceuticals, Inc., Antares Pharma, kaleo, Inc., Pfizer, Teva Pharmaceutical Industries Ltd., and Viatris Inc. Key players have adopted agreement and product approval as key developmental strategies to improve the product portfolio of the epinephrine market.

Key Benefits for Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the epinephrine market analysis from 2022 to 2032 to identify the prevailing epinephrine market opportunities.

The market research is offered along with information related to key drivers, restraints, and opportunities.

Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

In-depth analysis of the epinephrine market segmentation assists to determine the prevailing market opportunities.

Major countries in each region are mapped according to their revenue contribution to the global market.

Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

The report includes the analysis of the regional as well as global epinephrine market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Product Type

  • Auto-Injector
  • Prefilled Syringe
  • Others

By Application

  • Anaphylaxis
  • Cardiac Arrest
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores and Retail Pharmacies
  • Online Providers

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Colombia
    • Argentina
    • Rest Of La
  • Middle East and Africa
    • Gcc
    • South Africa
    • North Africa
    • Rest Of Mea

Key Market Players:

    • Adamis Pharmaceuticals Corporation
    • AdvaCare Pharma
    • ALK
    • Amneal Pharmaceuticals LLC.
    • Amphastar Pharmaceuticals, Inc.
    • Grand Pharma (China) Co., Ltd.
    • kaleo, Inc.
    • Pfizer
    • Teva Pharmaceutical Industries Ltd.
    • Viatris Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
  • 3.4. Market dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: EPINEPHRINE MARKET, BY PRODUCT TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Auto-Injector
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Prefilled Syringe
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Others
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country

CHAPTER 5: EPINEPHRINE MARKET, BY APPLICATION

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Anaphylaxis
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Cardiac Arrest
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Others
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country

CHAPTER 6: EPINEPHRINE MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospital Pharmacies
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Drug Stores and Retail Pharmacies
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Online Providers
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: EPINEPHRINE MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key market trends, growth factors and opportunities
    • 7.2.2. Market size and forecast, by Product Type
    • 7.2.3. Market size and forecast, by Application
    • 7.2.4. Market size and forecast, by Distribution Channel
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Market size and forecast, by Product Type
      • 7.2.5.1.2. Market size and forecast, by Application
      • 7.2.5.1.3. Market size and forecast, by Distribution Channel
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Market size and forecast, by Product Type
      • 7.2.5.2.2. Market size and forecast, by Application
      • 7.2.5.2.3. Market size and forecast, by Distribution Channel
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Market size and forecast, by Product Type
      • 7.2.5.3.2. Market size and forecast, by Application
      • 7.2.5.3.3. Market size and forecast, by Distribution Channel
  • 7.3. Europe
    • 7.3.1. Key market trends, growth factors and opportunities
    • 7.3.2. Market size and forecast, by Product Type
    • 7.3.3. Market size and forecast, by Application
    • 7.3.4. Market size and forecast, by Distribution Channel
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Market size and forecast, by Product Type
      • 7.3.5.1.2. Market size and forecast, by Application
      • 7.3.5.1.3. Market size and forecast, by Distribution Channel
      • 7.3.5.2. France
      • 7.3.5.2.1. Market size and forecast, by Product Type
      • 7.3.5.2.2. Market size and forecast, by Application
      • 7.3.5.2.3. Market size and forecast, by Distribution Channel
      • 7.3.5.3. UK
      • 7.3.5.3.1. Market size and forecast, by Product Type
      • 7.3.5.3.2. Market size and forecast, by Application
      • 7.3.5.3.3. Market size and forecast, by Distribution Channel
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Market size and forecast, by Product Type
      • 7.3.5.4.2. Market size and forecast, by Application
      • 7.3.5.4.3. Market size and forecast, by Distribution Channel
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Market size and forecast, by Product Type
      • 7.3.5.5.2. Market size and forecast, by Application
      • 7.3.5.5.3. Market size and forecast, by Distribution Channel
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Market size and forecast, by Product Type
      • 7.3.5.6.2. Market size and forecast, by Application
      • 7.3.5.6.3. Market size and forecast, by Distribution Channel
  • 7.4. Asia-Pacific
    • 7.4.1. Key market trends, growth factors and opportunities
    • 7.4.2. Market size and forecast, by Product Type
    • 7.4.3. Market size and forecast, by Application
    • 7.4.4. Market size and forecast, by Distribution Channel
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Market size and forecast, by Product Type
      • 7.4.5.1.2. Market size and forecast, by Application
      • 7.4.5.1.3. Market size and forecast, by Distribution Channel
      • 7.4.5.2. China
      • 7.4.5.2.1. Market size and forecast, by Product Type
      • 7.4.5.2.2. Market size and forecast, by Application
      • 7.4.5.2.3. Market size and forecast, by Distribution Channel
      • 7.4.5.3. India
      • 7.4.5.3.1. Market size and forecast, by Product Type
      • 7.4.5.3.2. Market size and forecast, by Application
      • 7.4.5.3.3. Market size and forecast, by Distribution Channel
      • 7.4.5.4. Australia
      • 7.4.5.4.1. Market size and forecast, by Product Type
      • 7.4.5.4.2. Market size and forecast, by Application
      • 7.4.5.4.3. Market size and forecast, by Distribution Channel
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Market size and forecast, by Product Type
      • 7.4.5.5.2. Market size and forecast, by Application
      • 7.4.5.5.3. Market size and forecast, by Distribution Channel
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Market size and forecast, by Product Type
      • 7.4.5.6.2. Market size and forecast, by Application
      • 7.4.5.6.3. Market size and forecast, by Distribution Channel
  • 7.5. Latin America
    • 7.5.1. Key market trends, growth factors and opportunities
    • 7.5.2. Market size and forecast, by Product Type
    • 7.5.3. Market size and forecast, by Application
    • 7.5.4. Market size and forecast, by Distribution Channel
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Market size and forecast, by Product Type
      • 7.5.5.1.2. Market size and forecast, by Application
      • 7.5.5.1.3. Market size and forecast, by Distribution Channel
      • 7.5.5.2. Colombia
      • 7.5.5.2.1. Market size and forecast, by Product Type
      • 7.5.5.2.2. Market size and forecast, by Application
      • 7.5.5.2.3. Market size and forecast, by Distribution Channel
      • 7.5.5.3. Argentina
      • 7.5.5.3.1. Market size and forecast, by Product Type
      • 7.5.5.3.2. Market size and forecast, by Application
      • 7.5.5.3.3. Market size and forecast, by Distribution Channel
      • 7.5.5.4. Rest Of La
      • 7.5.5.4.1. Market size and forecast, by Product Type
      • 7.5.5.4.2. Market size and forecast, by Application
      • 7.5.5.4.3. Market size and forecast, by Distribution Channel
  • 7.6. Middle East and Africa
    • 7.6.1. Key market trends, growth factors and opportunities
    • 7.6.2. Market size and forecast, by Product Type
    • 7.6.3. Market size and forecast, by Application
    • 7.6.4. Market size and forecast, by Distribution Channel
    • 7.6.5. Market size and forecast, by country
      • 7.6.5.1. Gcc
      • 7.6.5.1.1. Market size and forecast, by Product Type
      • 7.6.5.1.2. Market size and forecast, by Application
      • 7.6.5.1.3. Market size and forecast, by Distribution Channel
      • 7.6.5.2. South Africa
      • 7.6.5.2.1. Market size and forecast, by Product Type
      • 7.6.5.2.2. Market size and forecast, by Application
      • 7.6.5.2.3. Market size and forecast, by Distribution Channel
      • 7.6.5.3. North Africa
      • 7.6.5.3.1. Market size and forecast, by Product Type
      • 7.6.5.3.2. Market size and forecast, by Application
      • 7.6.5.3.3. Market size and forecast, by Distribution Channel
      • 7.6.5.4. Rest Of Mea
      • 7.6.5.4.1. Market size and forecast, by Product Type
      • 7.6.5.4.2. Market size and forecast, by Application
      • 7.6.5.4.3. Market size and forecast, by Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product mapping of top 10 player
  • 8.4. Competitive dashboard
  • 8.5. Competitive heatmap
  • 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

  • 9.1. Adamis Pharmaceuticals Corporation
    • 9.1.1. Company overview
    • 9.1.2. Key executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
    • 9.1.7. Key strategic moves and developments
  • 9.2. AdvaCare Pharma
    • 9.2.1. Company overview
    • 9.2.2. Key executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
    • 9.2.7. Key strategic moves and developments
  • 9.3. ALK
    • 9.3.1. Company overview
    • 9.3.2. Key executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
    • 9.3.7. Key strategic moves and developments
  • 9.4. Amneal Pharmaceuticals LLC.
    • 9.4.1. Company overview
    • 9.4.2. Key executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
    • 9.4.7. Key strategic moves and developments
  • 9.5. Amphastar Pharmaceuticals, Inc.
    • 9.5.1. Company overview
    • 9.5.2. Key executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Business performance
    • 9.5.7. Key strategic moves and developments
  • 9.6. Grand Pharma (China) Co., Ltd.
    • 9.6.1. Company overview
    • 9.6.2. Key executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Business performance
    • 9.6.7. Key strategic moves and developments
  • 9.7. kaleo, Inc.
    • 9.7.1. Company overview
    • 9.7.2. Key executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
    • 9.7.7. Key strategic moves and developments
  • 9.8. Pfizer
    • 9.8.1. Company overview
    • 9.8.2. Key executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
    • 9.8.7. Key strategic moves and developments
  • 9.9. Teva Pharmaceutical Industries Ltd.
    • 9.9.1. Company overview
    • 9.9.2. Key executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
    • 9.9.7. Key strategic moves and developments
  • 9.10. Viatris Inc.
    • 9.10.1. Company overview
    • 9.10.2. Key executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance
    • 9.10.7. Key strategic moves and developments

LIST OF TABLES

  • TABLE 01. GLOBAL EPINEPHRINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 02. EPINEPHRINE MARKET FOR AUTO-INJECTOR, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. EPINEPHRINE MARKET FOR PREFILLED SYRINGE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 04. EPINEPHRINE MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 05. GLOBAL EPINEPHRINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 06. EPINEPHRINE MARKET FOR ANAPHYLAXIS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 07. EPINEPHRINE MARKET FOR CARDIAC ARREST, BY REGION, 2022-2032 ($MILLION)
  • TABLE 08. EPINEPHRINE MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 09. GLOBAL EPINEPHRINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 10. EPINEPHRINE MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. EPINEPHRINE MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. EPINEPHRINE MARKET FOR ONLINE PROVIDERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. EPINEPHRINE MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. NORTH AMERICA EPINEPHRINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 15. NORTH AMERICA EPINEPHRINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 16. NORTH AMERICA EPINEPHRINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 17. NORTH AMERICA EPINEPHRINE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 18. U.S. EPINEPHRINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 19. U.S. EPINEPHRINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 20. U.S. EPINEPHRINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 21. CANADA EPINEPHRINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 22. CANADA EPINEPHRINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 23. CANADA EPINEPHRINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 24. MEXICO EPINEPHRINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 25. MEXICO EPINEPHRINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 26. MEXICO EPINEPHRINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 27. EUROPE EPINEPHRINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 28. EUROPE EPINEPHRINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 29. EUROPE EPINEPHRINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 30. EUROPE EPINEPHRINE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 31. GERMANY EPINEPHRINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 32. GERMANY EPINEPHRINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 33. GERMANY EPINEPHRINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 34. FRANCE EPINEPHRINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 35. FRANCE EPINEPHRINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 36. FRANCE EPINEPHRINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 37. UK EPINEPHRINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 38. UK EPINEPHRINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 39. UK EPINEPHRINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 40. ITALY EPINEPHRINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 41. ITALY EPINEPHRINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 42. ITALY EPINEPHRINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 43. SPAIN EPINEPHRINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 44. SPAIN EPINEPHRINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 45. SPAIN EPINEPHRINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 46. REST OF EUROPE EPINEPHRINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 47. REST OF EUROPE EPINEPHRINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 48. REST OF EUROPE EPINEPHRINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 49. ASIA-PACIFIC EPINEPHRINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 50. ASIA-PACIFIC EPINEPHRINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 51. ASIA-PACIFIC EPINEPHRINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 52. ASIA-PACIFIC EPINEPHRINE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 53. JAPAN EPINEPHRINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 54. JAPAN EPINEPHRINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 55. JAPAN EPINEPHRINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 56. CHINA EPINEPHRINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 57. CHINA EPINEPHRINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 58. CHINA EPINEPHRINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 59. INDIA EPINEPHRINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 60. INDIA EPINEPHRINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 61. INDIA EPINEPHRINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 62. AUSTRALIA EPINEPHRINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 63. AUSTRALIA EPINEPHRINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 64. AUSTRALIA EPINEPHRINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 65. SOUTH KOREA EPINEPHRINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 66. SOUTH KOREA EPINEPHRINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 67. SOUTH KOREA EPINEPHRINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 68. REST OF ASIA-PACIFIC EPINEPHRINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 69. REST OF ASIA-PACIFIC EPINEPHRINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 70. REST OF ASIA-PACIFIC EPINEPHRINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 71. LATIN AMERICA EPINEPHRINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 72. LATIN AMERICA EPINEPHRINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 73. LATIN AMERICA EPINEPHRINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 74. LATIN AMERICA EPINEPHRINE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 75. BRAZIL EPINEPHRINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 76. BRAZIL EPINEPHRINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 77. BRAZIL EPINEPHRINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 78. COLOMBIA EPINEPHRINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 79. COLOMBIA EPINEPHRINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 80. COLOMBIA EPINEPHRINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 81. ARGENTINA EPINEPHRINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 82. ARGENTINA EPINEPHRINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 83. ARGENTINA EPINEPHRINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 84. REST OF LA EPINEPHRINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 85. REST OF LA EPINEPHRINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 86. REST OF LA EPINEPHRINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 87. MIDDLE EAST AND AFRICA EPINEPHRINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 88. MIDDLE EAST AND AFRICA EPINEPHRINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 89. MIDDLE EAST AND AFRICA EPINEPHRINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 90. MIDDLE EAST AND AFRICA EPINEPHRINE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 91. GCC EPINEPHRINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 92. GCC EPINEPHRINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 93. GCC EPINEPHRINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 94. SOUTH AFRICA EPINEPHRINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 95. SOUTH AFRICA EPINEPHRINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 96. SOUTH AFRICA EPINEPHRINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 97. NORTH AFRICA EPINEPHRINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 98. NORTH AFRICA EPINEPHRINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 99. NORTH AFRICA EPINEPHRINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 100. REST OF MEA EPINEPHRINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 101. REST OF MEA EPINEPHRINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 102. REST OF MEA EPINEPHRINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 103. ADAMIS PHARMACEUTICALS CORPORATION: KEY EXECUTIVES
  • TABLE 104. ADAMIS PHARMACEUTICALS CORPORATION: COMPANY SNAPSHOT
  • TABLE 105. ADAMIS PHARMACEUTICALS CORPORATION: PRODUCT SEGMENTS
  • TABLE 106. ADAMIS PHARMACEUTICALS CORPORATION: SERVICE SEGMENTS
  • TABLE 107. ADAMIS PHARMACEUTICALS CORPORATION: PRODUCT PORTFOLIO
  • TABLE 108. ADAMIS PHARMACEUTICALS CORPORATION: KEY STRATERGIES
  • TABLE 109. ADVACARE PHARMA: KEY EXECUTIVES
  • TABLE 110. ADVACARE PHARMA: COMPANY SNAPSHOT
  • TABLE 111. ADVACARE PHARMA: PRODUCT SEGMENTS
  • TABLE 112. ADVACARE PHARMA: SERVICE SEGMENTS
  • TABLE 113. ADVACARE PHARMA: PRODUCT PORTFOLIO
  • TABLE 114. ADVACARE PHARMA: KEY STRATERGIES
  • TABLE 115. ALK: KEY EXECUTIVES
  • TABLE 116. ALK: COMPANY SNAPSHOT
  • TABLE 117. ALK: PRODUCT SEGMENTS
  • TABLE 118. ALK: SERVICE SEGMENTS
  • TABLE 119. ALK: PRODUCT PORTFOLIO
  • TABLE 120. ALK: KEY STRATERGIES
  • TABLE 121. AMNEAL PHARMACEUTICALS LLC.: KEY EXECUTIVES
  • TABLE 122. AMNEAL PHARMACEUTICALS LLC.: COMPANY SNAPSHOT
  • TABLE 123. AMNEAL PHARMACEUTICALS LLC.: PRODUCT SEGMENTS
  • TABLE 124. AMNEAL PHARMACEUTICALS LLC.: SERVICE SEGMENTS
  • TABLE 125. AMNEAL PHARMACEUTICALS LLC.: PRODUCT PORTFOLIO
  • TABLE 126. AMNEAL PHARMACEUTICALS LLC.: KEY STRATERGIES
  • TABLE 127. AMPHASTAR PHARMACEUTICALS, INC.: KEY EXECUTIVES
  • TABLE 128. AMPHASTAR PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
  • TABLE 129. AMPHASTAR PHARMACEUTICALS, INC.: PRODUCT SEGMENTS
  • TABLE 130. AMPHASTAR PHARMACEUTICALS, INC.: SERVICE SEGMENTS
  • TABLE 131. AMPHASTAR PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO
  • TABLE 132. AMPHASTAR PHARMACEUTICALS, INC.: KEY STRATERGIES
  • TABLE 133. GRAND PHARMA (CHINA) CO., LTD.: KEY EXECUTIVES
  • TABLE 134. GRAND PHARMA (CHINA) CO., LTD.: COMPANY SNAPSHOT
  • TABLE 135. GRAND PHARMA (CHINA) CO., LTD.: PRODUCT SEGMENTS
  • TABLE 136. GRAND PHARMA (CHINA) CO., LTD.: SERVICE SEGMENTS
  • TABLE 137. GRAND PHARMA (CHINA) CO., LTD.: PRODUCT PORTFOLIO
  • TABLE 138. GRAND PHARMA (CHINA) CO., LTD.: KEY STRATERGIES
  • TABLE 139. KALEO, INC.: KEY EXECUTIVES
  • TABLE 140. KALEO, INC.: COMPANY SNAPSHOT
  • TABLE 141. KALEO, INC.: PRODUCT SEGMENTS
  • TABLE 142. KALEO, INC.: SERVICE SEGMENTS
  • TABLE 143. KALEO, INC.: PRODUCT PORTFOLIO
  • TABLE 144. KALEO, INC.: KEY STRATERGIES
  • TABLE 145. PFIZER: KEY EXECUTIVES
  • TABLE 146. PFIZER: COMPANY SNAPSHOT
  • TABLE 147. PFIZER: PRODUCT SEGMENTS
  • TABLE 148. PFIZER: SERVICE SEGMENTS
  • TABLE 149. PFIZER: PRODUCT PORTFOLIO
  • TABLE 150. PFIZER: KEY STRATERGIES
  • TABLE 151. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
  • TABLE 152. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 153. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
  • TABLE 154. TEVA PHARMACEUTICAL INDUSTRIES LTD.: SERVICE SEGMENTS
  • TABLE 155. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
  • TABLE 156. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGIES
  • TABLE 157. VIATRIS INC.: KEY EXECUTIVES
  • TABLE 158. VIATRIS INC.: COMPANY SNAPSHOT
  • TABLE 159. VIATRIS INC.: PRODUCT SEGMENTS
  • TABLE 160. VIATRIS INC.: SERVICE SEGMENTS
  • TABLE 161. VIATRIS INC.: PRODUCT PORTFOLIO
  • TABLE 162. VIATRIS INC.: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 01. EPINEPHRINE MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF EPINEPHRINE MARKET,2022-2032
  • FIGURE 03. TOP IMPACTING FACTORS IN EPINEPHRINE MARKET
  • FIGURE 04. TOP INVESTMENT POCKETS IN EPINEPHRINE MARKET (2023-2032)
  • FIGURE 05. BARGAINING POWER OF SUPPLIERS
  • FIGURE 06. BARGAINING POWER OF BUYERS
  • FIGURE 07. THREAT OF SUBSTITUTION
  • FIGURE 08. THREAT OF SUBSTITUTION
  • FIGURE 09. COMPETITIVE RIVALRY
  • FIGURE 10. GLOBAL EPINEPHRINE MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 11. EPINEPHRINE MARKET, BY PRODUCT TYPE, 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF EPINEPHRINE MARKET FOR AUTO-INJECTOR, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF EPINEPHRINE MARKET FOR PREFILLED SYRINGE, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF EPINEPHRINE MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 15. EPINEPHRINE MARKET, BY APPLICATION, 2022 AND 2032(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF EPINEPHRINE MARKET FOR ANAPHYLAXIS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF EPINEPHRINE MARKET FOR CARDIAC ARREST, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF EPINEPHRINE MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 19. EPINEPHRINE MARKET, BY DISTRIBUTION CHANNEL, 2022 AND 2032(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF EPINEPHRINE MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF EPINEPHRINE MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 22. COMPARATIVE SHARE ANALYSIS OF EPINEPHRINE MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 23. EPINEPHRINE MARKET BY REGION, 2022 AND 2032(%)
  • FIGURE 24. U.S. EPINEPHRINE MARKET, 2022-2032 ($MILLION)
  • FIGURE 25. CANADA EPINEPHRINE MARKET, 2022-2032 ($MILLION)
  • FIGURE 26. MEXICO EPINEPHRINE MARKET, 2022-2032 ($MILLION)
  • FIGURE 27. GERMANY EPINEPHRINE MARKET, 2022-2032 ($MILLION)
  • FIGURE 28. FRANCE EPINEPHRINE MARKET, 2022-2032 ($MILLION)
  • FIGURE 29. UK EPINEPHRINE MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. ITALY EPINEPHRINE MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. SPAIN EPINEPHRINE MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. REST OF EUROPE EPINEPHRINE MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. JAPAN EPINEPHRINE MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. CHINA EPINEPHRINE MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. INDIA EPINEPHRINE MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. AUSTRALIA EPINEPHRINE MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. SOUTH KOREA EPINEPHRINE MARKET, 2022-2032 ($MILLION)
  • FIGURE 38. REST OF ASIA-PACIFIC EPINEPHRINE MARKET, 2022-2032 ($MILLION)
  • FIGURE 39. BRAZIL EPINEPHRINE MARKET, 2022-2032 ($MILLION)
  • FIGURE 40. COLOMBIA EPINEPHRINE MARKET, 2022-2032 ($MILLION)
  • FIGURE 41. ARGENTINA EPINEPHRINE MARKET, 2022-2032 ($MILLION)
  • FIGURE 42. REST OF LA EPINEPHRINE MARKET, 2022-2032 ($MILLION)
  • FIGURE 43. GCC EPINEPHRINE MARKET, 2022-2032 ($MILLION)
  • FIGURE 44. SOUTH AFRICA EPINEPHRINE MARKET, 2022-2032 ($MILLION)
  • FIGURE 45. NORTH AFRICA EPINEPHRINE MARKET, 2022-2032 ($MILLION)
  • FIGURE 46. REST OF MEA EPINEPHRINE MARKET, 2022-2032 ($MILLION)
  • FIGURE 47. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 48. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 49. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 50. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 51. COMPETITIVE DASHBOARD
  • FIGURE 52. COMPETITIVE HEATMAP: EPINEPHRINE MARKET
  • FIGURE 53. TOP PLAYER POSITIONING, 2022